About Oxygenta Pharmaceutical Limited
Data last updated:
Oxygenta Pharmaceutical Limited is a public limited company based in Medak, Telangana, India. It operates in the organic chemicals and compounds segment of the chemicals and materials sector. It was incorporated on 27 November 1990 and has been in existence for over 36 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN L24110TG1990PLC012038. Its GSTIN is 36AADCS2216C1ZW (Telangana). The company holds 2 GST registrations, of which 1 is active. Its shares are listed on BSE: 524636.
The company has an authorised share capital of ₹37.5 Cr and a paid-up capital of ₹36.98 Cr. It was formerly known as S.S. Organics Pvt Ltd and S.S. Organics Ltd. It is led by directors including Chandra Mouliswar Reddy Gangavaram (Whole-Time Director) and Balasubba Reddy Mamilla (Whole-Time Director).
Its last annual general meeting (AGM) was held on 19 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Survey No.252/1 Aroor Village Sadasivapet Mandal Medak District, Telangana, India.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹112.98 Cr, a growth of 3.4% compared to the previous year. For the same year it recorded a net loss of ₹17.56 Cr (net margin -15.5%) and EBITDA of -₹15.32 Cr (EBITDA margin -13.6%). Total assets are valued at ₹67.86 Cr (up 80.1% YoY).
The company has about 98 employees on its provident fund (EPFO) records.
The company is associated with 2 brands: Oxygenta Pharmaceutical Ltd and S S Organics. As per MCA filings, the company has open charges of ₹46.6 Cr and satisfied charges of ₹55.7 Cr on record. Court records list 80 cases involving the company, including 25 filed by the company and 50 filed against it; 3 cases are pending. The company has 13 deals on record (10 market trades, 2 secondary share transfers, 1 funding round), with disclosed funding of ₹4 Cr; the latest was in February 2026.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website oxygentapharma.com.
- EmailLocked
- TelephoneLocked
- Website
- Social Media
- Registered AddressSurvey No.252/1 Aroor Village Sadasivapet Mandal Medak District, Telangana, India
- IndustryChemicals and Materials, Organic Chemicals & Compounds
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Financials of Oxygenta Pharmaceutical Limited FY 2025-26 filings available
Oxygenta Pharmaceutical Limited reported revenue of ₹112.98 Cr (up 3.4% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 113 | 109 | 39.64 | 30.99 | 60.52 | 52.03 | 13.72 |
| Revenue growth | +3.4% | +175.7% | +27.9% | -48.8% | +16.3% | +279.2% | - |
| EBITDA | (15.32) | (9.82) | (9.71) | (7.97) | 0.67 | 3.85 | (7.86) |
| EBITDA margin | -13.6% | -9.0% | -24.5% | -25.7% | +1.1% | +7.4% | -57.3% |
| Profit before tax | (22.17) | (14.35) | (13.86) | (11.37) | (0.48) | 3.15 | (5.93) |
| Net profit | (17.56) | (10.35) | (3.51) | (10.85) | (1.03) | 0.90 | (9.77) |
| Net profit margin | -15.5% | -9.5% | -8.9% | -35.0% | -1.7% | +1.7% | -71.2% |
| EPS (₹) | (4.75) | (2.78) | (1.04) | (8.15) | (0.43) | 2.87 | (5.67) |
| Balance sheet | |||||||
| Total assets | 67.86 | 37.67 | 37.73 | 25.45 | 22.73 | 17.88 | 3.12 |
| Net worth | (42.69) | (25.64) | (20.13) | (46.20) | (34.63) | (38.02) | (40.95) |
| Total debt | 110 | 62.23 | 57.23 | 68.00 | 52.13 | 47.89 | 26.92 |
| Cash & bank | 2.15 | 0.12 | 0.10 | 0.11 | 0.16 | 0.45 | 0.12 |
| Net working capital | (0.40) | (14.20) | (1.35) | (2.13) | 2.58 | 1.29 | (8.72) |
| Cash flow | |||||||
| Cash from operations | (27.75) | 2.83 | (13.05) | (1.63) | (1.68) | (1.62) | (2.59) |
| Cash from investing | (14.39) | (11.32) | (4.09) | (9.64) | (4.94) | (6.72) | (0.50) |
| Cash from financing | 42.56 | 8.49 | 17.13 | 11.22 | 6.33 | 8.67 | 3.19 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 37.00 | 49.61 | 33.93 | 14.30 | 15.13 | 49.47 | 33.21 | 14.01 |
| Revenue growth (YoY) | +144.6% | +0.3% | +2.2% | +2.1% | +19.9% | - | - | - |
| Other income | 0.02 | 0.17 | 0.00 | (0.06) | 0.17 | 0.05 | 0.49 | 0.75 |
| Total expenses | 36.45 | 49.50 | 38.01 | 18.88 | 21.98 | 51.42 | 37.56 | 16.18 |
| EBITDA | 0.55 | 0.11 | (4.08) | (4.58) | (6.85) | (1.95) | (4.35) | (2.17) |
| EBITDA margin | +1.5% | +0.2% | -12.0% | -32.0% | -45.3% | -3.9% | -13.1% | -15.5% |
| Depreciation | 0.62 | (0.24) | 0.86 | 0.86 | 0.85 | (0.23) | 0.71 | 0.66 |
| Interest | 2.46 | 1.81 | 1.39 | 0.95 | 0.63 | 2.13 | 0.39 | 0.69 |
| Profit before tax | (2.51) | (1.29) | (6.33) | (6.45) | (8.16) | (3.80) | (4.96) | (2.77) |
| Tax | (0.40) | 0.42 | (1.48) | (1.51) | (2.04) | (1.65) | (1.03) | 0.08 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 37.00 | 49.61 | 33.93 | 14.30 | 15.13 | 49.47 | 33.21 | 14.01 |
| Revenue growth (YoY) | +144.6% | +0.3% | +2.2% | +2.1% | +19.9% | - | - | - |
| Other income | 0.02 | 0.17 | 0.00 | (0.06) | 0.17 | 0.05 | 0.49 | 0.75 |
| Total expenses | 36.45 | 49.50 | 38.01 | 18.88 | 21.98 | 51.42 | 37.56 | 16.18 |
| EBITDA | 0.55 | 0.11 | (4.08) | (4.58) | (6.85) | (1.95) | (4.35) | (2.17) |
| EBITDA margin | +1.5% | +0.2% | -12.0% | -32.0% | -45.3% | -3.9% | -13.1% | -15.5% |
| Depreciation | 0.62 | (0.24) | 0.86 | 0.86 | 0.85 | (0.23) | 0.71 | 0.66 |
| Interest | 2.46 | 1.81 | 1.39 | 0.95 | 0.63 | 2.13 | 0.39 | 0.69 |
| Profit before tax | (2.51) | (1.29) | (6.33) | (6.45) | (8.16) | (3.80) | (4.96) | (2.77) |
| Tax | (0.40) | 0.42 | (1.48) | (1.51) | (2.04) | (1.65) | (1.03) | 0.08 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 113 | 109 | 39.64 | 30.99 | 60.52 | 52.03 | 13.72 |
| Revenue growth | +3.4% | +175.7% | +27.9% | -48.8% | +16.3% | +279.2% | - |
| Other income | 0.29 | 1.31 | 0.10 | 0.14 | 1.36 | 2.28 | 4.02 |
| Total expenses | 128 | 119 | 49.35 | 38.96 | 59.85 | 48.18 | 21.58 |
| Employee cost | 7.61 | 6.76 | 5.96 | 5.74 | 0.58 | 4.08 | 2.50 |
| EBITDA | (15.32) | (9.82) | (9.71) | (7.97) | 0.67 | 3.85 | (7.86) |
| EBITDA margin | -13.6% | -9.0% | -24.5% | -25.7% | +1.1% | +7.4% | -57.3% |
| Depreciation | 2.32 | 3.61 | 2.66 | 2.05 | 1.59 | 1.20 | 1.00 |
| Interest | 4.82 | 2.23 | 1.59 | 1.49 | 0.92 | 1.78 | 1.09 |
| Profit before tax | (22.17) | (14.35) | (13.86) | (11.37) | (0.48) | 3.15 | (5.93) |
| Tax | (4.61) | (4.05) | (10.39) | 0.20 | 0.12 | 0.21 | (0.15) |
| Net profit | (17.56) | (10.35) | (3.51) | (10.85) | (1.03) | 0.90 | (9.77) |
| Net profit margin | -15.5% | -9.5% | -8.9% | -35.0% | -1.7% | +1.7% | -71.2% |
| EPS (₹) | (4.75) | (2.78) | (1.04) | (8.15) | (0.43) | 2.87 | (5.67) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 36.98 | 36.98 | 33.48 | 14.20 | 14.20 | 10.20 | 10.20 |
| Reserves & surplus | (79.67) | (62.62) | (54.17) | (60.40) | (48.83) | (48.22) | (51.15) |
| Shareholders' funds (net worth) | (42.69) | (25.64) | (20.13) | (46.20) | (34.63) | (38.02) | (40.95) |
| Secured loans | 43.11 | 13.92 | 10.86 | 41.99 | 33.86 | 2.85 | 0.50 |
| Unsecured loans | 66.45 | 48.31 | 46.37 | 26.01 | 18.27 | 45.04 | 26.42 |
| Total debt | 110 | 62.23 | 57.23 | 68.00 | 52.13 | 47.89 | 26.92 |
| Total liabilities | 67.86 | 37.67 | 37.73 | 25.45 | 22.73 | 17.88 | 3.12 |
| Assets | |||||||
| Gross block | 74.58 | 61.49 | 50.53 | 46.43 | 36.44 | 31.18 | 25.10 |
| Net block | 47.60 | 36.83 | 29.35 | 27.91 | 19.98 | 16.31 | 11.42 |
| Capital work in progress | 0.00 | 0.23 | 0.00 | 0.00 | 0.34 | 0.65 | 0.00 |
| Investments | 0.47 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
| Inventories | 29.42 | 20.51 | 13.72 | 11.71 | 7.28 | 12.11 | 4.25 |
| Sundry debtors | 10.03 | 5.10 | 7.36 | 10.16 | 1.58 | 1.61 | 0.42 |
| Cash & bank balances | 2.15 | 0.12 | 0.10 | 0.11 | 0.16 | 0.45 | 0.12 |
| Loans & advances | 9.83 | 5.21 | 2.93 | 3.04 | 0.55 | 1.77 | 1.98 |
| Total current assets | 51.43 | 30.94 | 24.11 | 25.02 | 9.57 | 15.94 | 6.77 |
| Total current liabilities | 51.83 | 45.14 | 25.46 | 27.15 | 6.99 | 14.65 | 15.49 |
| Net working capital | (0.40) | (14.20) | (1.35) | (2.13) | 2.58 | 1.29 | (8.72) |
| Total assets | 67.86 | 37.67 | 37.73 | 25.45 | 22.73 | 17.88 | 3.12 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.00 | 0.00 | 0.11 | 0.16 | 0.45 | 0.12 | 0.02 |
| Net cash from operating activities | (27.75) | 2.83 | (13.05) | (1.63) | (1.68) | (1.62) | (2.59) |
| Net cash from investing activities | (14.39) | (11.32) | (4.09) | (9.64) | (4.94) | (6.72) | (0.50) |
| Net cash from financing activities | 42.56 | 8.49 | 17.13 | 11.22 | 6.33 | 8.67 | 3.19 |
| Net change in cash | 0.42 | 0.00 | (0.01) | (0.05) | (0.29) | 0.33 | 0.10 |
| Closing cash | 2.15 | 0.12 | 0.10 | 0.11 | 0.16 | 0.45 | 0.12 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +3.4% | +175.7% | +27.9% | -48.8% | +16.3% | +279.2% | - |
| EBITDA growth | -56.0% | -1.1% | -21.8% | -1289.6% | -82.6% | +149.0% | - |
| PBT growth | -54.5% | -3.5% | -21.9% | -2268.8% | - | +9998.0% | -69.4% |
| Net income growth | -69.7% | -194.9% | +67.7% | -953.4% | -214.4% | +109.2% | - |
| Revenue CAGR (3Y) | +53.9% | +21.8% | -8.7% | +31.2% | +43.4% | +59.3% | +19.0% |
| EBITDA CAGR (3Y) | +24.3% | - | - | +0.5% | - | - | +17.5% |
| Profitability & leverage | |||||||
| Net income margin | -15.5% | -9.4% | -8.8% | -37.3% | -1.0% | +5.7% | -42.1% |
| Return on capital employed | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | +7.9% | 0.0% |
| Return on net worth | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -5.8% | 0.0% |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | -27.32 | -16.60 | -12.85 | -14.87 | -100.00 | 67.17 | -12.30 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.66 | 1.95 | 0.82 | 0.75 | 1.79 | 1.85 | 0.55 |
| Inventory turnover | 4.53 | 6.39 | 3.12 | 3.26 | 6.24 | 6.36 | 2.86 |
| Debtors turnover | 14.93 | 17.54 | 4.53 | 5.28 | 37.94 | 51.26 | 29.51 |
| EPS (₹) | (4.75) | (2.78) | (1.04) | (8.15) | (0.43) | 2.87 | (5.67) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | (11.54) | (6.93) | (6.18) | (32.53) | (24.38) | (37.27) | (40.14) |
Auditor Details of Oxygenta Pharmaceutical Limited
Oxygenta Pharmaceutical Limited is audited by Gowri Shankar and associates for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Gowri Shankar and associates | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Oxygenta Pharmaceutical Limited
Oxygenta Pharmaceutical has 8 current directors and 41 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Vedavathi Gangavaram Also directs: Virupaksha Life Sciences LLP, Virupaksha Minerals LLP, Virupaksha Organics Limited and 3 more | Director | 20 Jun 2025 | 1 Years 3 Months | Current |
| Veera Reddy Arava Also directs: Virupaksha Organics Limited | Director | 20 Jun 2025 | 1 Years 3 Months | Current |
| Sidda Reddy Kanuparthi Also directs: Virupaksha Organics Limited, Kanuparthi Trading LLP, Harinandan Enterprises Private Limited and 1 more | Director | 20 Jun 2025 | 1 Years 3 Months | Current |
| Sharvari Swapnil Shinde | Director | 20 Jun 2025 | 1 Years 3 Months | Current |
| Chandra Mouliswar Reddy Gangavaram Also directs: Virupaksha Life Sciences LLP, Virupaksha Minerals LLP, Virupaksha Organics Limited and 3 more | Whole-Time Director | 20 Jun 2025 | 1 Years 3 Months | Current |
| Balasubba Reddy Mamilla | Whole-Time Director | 20 Jun 2025 | 1 Years 3 Months | Current |
Shareholding Pattern of Oxygenta Pharmaceutical Limited
Shareholding for the quarter ended Sep 2026: promoters hold 56.50%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 43.50%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 56.50% | 56.50% | 55.90% | 58.00% |
| Public | 43.50% | 43.50% | 44.10% | 42.00% |
Charges & Borrowings of Oxygenta Pharmaceutical Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Jun 2025 | Others | ₹46.6 Cr | Open |
| 02 Sep 2022 | Others | ₹5 Cr | Satisfied |
| 02 Sep 2022 | Others | ₹10 Cr | Satisfied |
| 21 Dec 2020 | Others | ₹6.7 Cr | Satisfied |
| 10 Sep 2020 | Others | ₹31.5 Cr | Satisfied |
Total charge records: 6 View all charges
Deals & Funding of Oxygenta Pharmaceutical Limited
Oxygenta Pharmaceutical Limited has 13 deals on record (10 market trades, 2 secondary share transfers, 1 funding round), with disclosed funding of ₹4 Cr; the latest was in February 2026.
Deals on record (5 of 13)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Feb 2026 | Market trade | ₹1.41 Cr | Buyer: Virupaksha Organics Limited Seller: an individual |
| Dec 2025 | Market trade | ₹1.11 Cr | Buyer: Virupaksha Organics Limited Seller: an individual |
| Aug 2021 | Funding round | ₹4 Cr | |
| Sep 2019 | Secondary share transfer | Undisclosed | Buyer: 4 individuals Seller: Others - S S Organics Ltd |
| Dec 2007 | Market trade | ₹17.1 Lakh | Seller: Regal Corporate Advisors Private Limited |
Full deal history
All 13 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal Cases of Oxygenta Pharmaceutical Limited
Oxygenta Pharmaceutical Limited has 80 court cases on record: 25 filed by Oxygenta Pharmaceutical, 50 filed against it, 5 where it is another party. 3 cases are pending and 77 are disposed. Status as checked between 21 Sep 2026 and 04 Oct 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 49 | 43 | 0 |
| High courts | 30 | 6 | 2 |
| NCLAT | 1 | 1 | 1 |
Cases on record (5 of 80)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Hyderabad CCC, Telangana | Criminal complaint | Filed against the company by Aurobindo Pharma Ltd | Disposed |
| District court, Mumbai CMM Courts, Maharashtra | Civil suit | Filed against the company by Mangalam Drugs and Organics Limited | Disposed |
| District court, Hyderabad CCC, Telangana | Petition | Filed by the company against Aurobindo Pharma Ltd | Disposed |
| High Court for State of Telangana | Arbitration matter | Filed by the company against Aurobindo Pharma Ltd | Disposed |
| District court, Hyderabad CCC, Telangana | Criminal complaint | Filed against the company by P.R. Drugs Private Limited and 1 other | Disposed |
Full case history
All 80 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Associated Brands with Oxygenta Pharmaceutical Limited
Oxygenta Pharmaceutical operates two associated brands: Oxygenta Pharmaceutical Ltd and S S ORGANICS. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Finished products and APIs are manufactured for therapeutic categories. | ssorganics.co.in | |
| Manufacturing of drugs, pharmaceutical preparations, and organic fine chemicals in India. | oxygentapharma.com |
Employees and EPFO Compliance at Oxygenta Pharmaceutical Limited
Oxygenta Pharmaceutical Limited has a workforce of 98 employees as of Sep 11, 2024.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Name History of Oxygenta Pharmaceutical Limited
Oxygenta Pharmaceutical has undergone 2 name changes throughout its history. The company was previously known as S.S. Organics Pvt Ltd, and S.S. Organics Ltd.. The current legal name is Oxygenta Pharmaceutical Limited.
| Company Name | Status |
|---|---|
| Oxygenta Pharmaceutical Limited | Current |
| S.S. Organics Pvt Ltd | Previous |
| S.S. Organics Ltd. | Previous |
CIN History of Oxygenta Pharmaceutical Limited
Oxygenta Pharmaceutical has one previous CIN (Corporate Identification Number): L24110AP1990PLC012038. The current CIN is L24110TG1990PLC012038, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24110TG1990PLC012038 | Current |
| L24110AP1990PLC012038 | Previous |
News related to Oxygenta Pharmaceutical Limited
Recent Activity on Oxygenta Pharmaceutical Limited
Oxygenta Pharmaceutical Limited has 73 board changes on record since 2006: 41 appointments and 32 cessations. The latest: Amireddy Venkatesu Reddy was appointed as Additional Director on 23 May 2026.
77 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Oxygenta Pharmaceutical Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Oxygenta Pharmaceutical Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Oxygenta Pharmaceutical Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Oxygenta Pharmaceutical Limited
Oxygenta Pharmaceutical has 2 GST registrations: 1 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AADCS2216C1ZW | Telangana | Active | 01 Jul 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Oxygenta Pharmaceutical Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Oxygenta Pharmaceutical Limited
Oxygenta Pharmaceutical is an active public limited company based in Medak, Telangana, India. The company works in organic chemicals and compounds, within the chemicals and materials industry. It was incorporated on 27 November 1990 (36+ years old) and is registered under CIN L24110TG1990PLC012038. Listed on BSE: 524636.
Oxygenta Pharmaceutical reported revenue of ₹112.98 Cr for FY 2025-26 (up 3.4% YoY) based on standalone financials.
Oxygenta Pharmaceutical has 8 current directors:
- Chandra Mouliswar Reddy Gangavaram - Whole-Time Director
- Balasubba Reddy Mamilla - Whole-Time Director
- Vedavathi Gangavaram - Director
- Veera Reddy Arava - Director
- Sidda Reddy Kanuparthi - Director
- Sharvari Swapnil Shinde - Director
- Janardhana Reddy Yeddula - Additional Director
- Amireddy Venkatesu Reddy - Additional Director
The GSTIN of Oxygenta Pharmaceutical is 36AADCS2216C1ZW, registered in Telangana. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Oxygenta Pharmaceutical is L24110TG1990PLC012038. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Oxygenta Pharmaceutical is listed on BSE with code 524636.
Oxygenta Pharmaceutical has 80 court cases on record: 25 filed by the company and 50 filed against it. 3 are pending. Most are in the district courts.
Oxygenta Pharmaceutical was incorporated on 27 November 1990, making it 36+ years old. It is registered with the Registrar of Companies, Hyderabad.
Oxygenta Pharmaceutical has 13 deals on record (10 market trades, 2 secondary share transfers, 1 funding round), with disclosed funding of ₹4 Cr; the latest was in February 2026.
Amireddy Venkatesu Reddy was appointed as Additional Director on 23 May 2026. Janardhana Reddy Yeddula was appointed as Additional Director on 23 May 2026. Prasad Reddy Battinapatla was appointed as CFO on 02 Dec 2025. Oxygenta Pharmaceutical has 73 board changes on record in total.